Pharmacokinetic/pharmacodynamic	pharmacokinetic/pharmacodynamic	O	O
assessment	assessment	O	O
of	of	O	O
the	the	O	O
effects	effects	O	O
of	of	O	O
E4031	e4031	O	O
,	,	O	O
cisapride	cisapride	S_chemical	O
,	,	O	O
terfenadine	terfenadine	S_chemical	O
and	and	O	O
terodiline	terodiline	S_chemical	O
on	on	O	O
monophasic	monophasic	O	O
action	action	O	O
potential	potential	O	O
duration	duration	O	O
in	in	O	O
dog.1	dog.1	O	O
.	.	O	O

Torsades	torsades	O	B_disease
de	de	O	I_disease
pointes	pointes	O	I_disease
(	(	O	O
TDP	tdp	O	S_disease
)	)	O	O
is	is	O	O
a	a	O	O
potentially	potentially	O	O
fatal	fatal	O	O
ventricular	ventricular	O	B_disease
tachycardia	tachycardia	O	S_disease
associated	associated	O	O
with	with	O	O
increases	increases	O	O
in	in	O	O
QT	qt	O	O
interval	interval	O	O
and	and	O	O
monophasic	monophasic	O	O
action	action	O	O
potential	potential	O	O
duration	duration	O	O
(	(	O	O
MAPD	mapd	O	O
)	)	O	O
.	.	O	O

TDP	tdp	O	S_disease
is	is	O	O
a	a	O	O
side-effect	side-effect	O	O
that	that	O	O
has	has	O	O
led	led	O	O
to	to	O	O
withdrawal	withdrawal	O	O
of	of	O	O
several	several	O	O
drugs	drugs	O	O
from	from	O	O
the	the	O	O
market	market	O	O
(	(	O	O
e.g.	e.g.	O	O
terfenadine	terfenadine	S_chemical	O
and	and	O	O
terodiline	terodiline	S_chemical	O
)	)	O	O
.	.	O	O

2	2	O	O
.	.	O	O

The	the	O	O
potential	potential	O	O
of	of	O	O
compounds	compounds	O	O
to	to	O	O
cause	cause	O	O
TDP	tdp	O	S_disease
was	was	O	O
evaluated	evaluated	O	O
by	by	O	O
monitoring	monitoring	O	O
their	their	O	O
effects	effects	O	O
on	on	O	O
MAPD	mapd	O	O
in	in	O	O
dog	dog	O	O
.	.	O	O

Four	four	O	O
compounds	compounds	O	O
known	known	O	O
to	to	O	O
increase	increase	O	O
QT	qt	O	O
interval	interval	O	O
and	and	O	O
cause	cause	O	O
TDP	tdp	O	S_disease
were	were	O	O
investigated	investigated	O	O
:	:	O	O
terfenadine	terfenadine	S_chemical	O
,	,	O	O
terodiline	terodiline	S_chemical	O
,	,	O	O
cisapride	cisapride	S_chemical	O
and	and	O	O
E4031	e4031	O	O
.	.	O	O

On	on	O	O
the	the	O	O
basis	basis	O	O
that	that	O	O
only	only	O	O
free	free	O	O
drug	drug	O	O
in	in	O	O
the	the	O	O
systemic	systemic	O	O
circulation	circulation	O	O
will	will	O	O
elicit	elicit	O	O
a	a	O	O
pharmacological	pharmacological	O	O
response	response	O	O
target	target	O	O
,	,	O	O
free	free	O	O
concentrations	concentrations	O	O
in	in	O	O
plasma	plasma	O	O
were	were	O	O
selected	selected	O	O
to	to	O	O
mimic	mimic	O	O
the	the	O	O
free	free	O	O
drug	drug	O	O
exposures	exposures	O	O
in	in	O	O
man	man	O	O
.	.	O	O

Infusion	infusion	O	O
regimens	regimens	O	O
were	were	O	O
designed	designed	O	O
that	that	O	O
rapidly	rapidly	O	O
achieved	achieved	O	O
and	and	O	O
maintained	maintained	O	O
target-free	target-free	O	O
concentrations	concentrations	O	O
of	of	O	O
these	these	O	O
drugs	drugs	O	O
in	in	O	O
plasma	plasma	O	O
and	and	O	O
data	data	O	O
on	on	O	O
the	the	O	O
relationship	relationship	O	O
between	between	O	O
free	free	O	O
concentration	concentration	O	O
and	and	O	O
changes	changes	O	O
in	in	O	O
MAPD	mapd	O	O
were	were	O	O
obtained	obtained	O	O
for	for	O	O
these	these	O	O
compounds	compounds	O	O
.	.	O	O

3	3	O	O
.	.	O	O

These	these	O	O
data	data	O	O
indicate	indicate	O	O
that	that	O	O
the	the	O	O
free	free	O	O
ED50	ed50	O	O
in	in	O	O
plasma	plasma	O	O
for	for	O	O
terfenadine	terfenadine	S_chemical	O
(	(	O	O
1.9	1.9	O	O
nM	nm	O	O
)	)	O	O
,	,	O	O
terodiline	terodiline	S_chemical	O
(	(	O	O
76	76	O	O
nM	nm	O	O
)	)	O	O
,	,	O	O
cisapride	cisapride	S_chemical	O
(	(	O	O
11	11	O	O
nM	nm	O	O
)	)	O	O
and	and	O	O
E4031	e4031	O	O
(	(	O	O
1.9	1.9	O	O
nM	nm	O	O
)	)	O	O
closely	closely	O	O
correlate	correlate	O	O
with	with	O	O
the	the	O	O
free	free	O	O
concentration	concentration	O	O
in	in	O	O
man	man	O	O
causing	causing	O	O
QT	qt	O	O
effects	effects	O	O
.	.	O	O

For	for	O	O
compounds	compounds	O	O
that	that	O	O
have	have	O	O
shown	shown	O	O
TDP	tdp	O	S_disease
in	in	O	O
the	the	O	O
clinic	clinic	O	O
(	(	O	O
terfenadine	terfenadine	S_chemical	O
,	,	O	O
terodiline	terodiline	S_chemical	O
,	,	O	O
cisapride	cisapride	S_chemical	O
)	)	O	O
there	there	O	O
is	is	O	O
little	little	O	O
differentiation	differentiation	O	O
between	between	O	O
the	the	O	O
dog	dog	O	O
ED50	ed50	O	O
and	and	O	O
the	the	O	O
efficacious	efficacious	O	O
free	free	O	O
plasma	plasma	O	O
concentrations	concentrations	O	O
in	in	O	O
man	man	O	O
(	(	O	O
<	<	O	O
10-fold	10-fold	O	O
)	)	O	O
reflecting	reflecting	O	O
their	their	O	O
limited	limited	O	O
safety	safety	O	O
margins	margins	O	O
.	.	O	O

These	these	O	O
data	data	O	O
underline	underline	O	O
the	the	O	O
need	need	O	O
to	to	O	O
maximize	maximize	O	O
the	the	O	O
therapeutic	therapeutic	O	O
ratio	ratio	O	O
with	with	O	O
respect	respect	O	O
to	to	O	O
TDP	tdp	O	S_disease
in	in	O	O
potential	potential	O	O
development	development	O	O
candidates	candidates	O	O
and	and	O	O
the	the	O	O
importance	importance	O	O
of	of	O	O
using	using	O	O
free	free	O	O
drug	drug	O	O
concentrations	concentrations	O	O
in	in	O	O
pharmacokinetic/pharmacodynamic	pharmacokinetic/pharmacodynamic	O	O
studies	studies	O	O
.	.	O	O

